CytomX Therapeutics Total Current Liabilities Over Time
| CTMX Stock | USD 1.06 0.04 3.92% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out CytomX Therapeutics Performance and CytomX Therapeutics Correlation. CytomX |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.819 | Earnings Share 0.16 | Revenue Per Share 1.518 | Quarterly Revenue Growth 0.267 | Return On Assets 0.0233 |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Liabilities Analysis
Compare CytomX Therapeutics and related stocks such as Spero Therapeutics, Neoleukin Therapeutics, and Instil Bio Total Current Liabilities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPRO | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M | 6.9 M | 8.2 M | 12.3 M | 26.7 M | 14.3 M | 18.7 M | 21.6 M | 37.2 M | 18.6 M |
| TIL | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 13.3 M | 41.4 M | 32.8 M | 10.6 M | 10 M |
| NXTC | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 10.3 M | 15 M | 10.3 M | 6.6 M | 9.1 M | 6.9 M | 9.6 M |
| ASMB | 4.7 M | 2.5 M | 2.7 M | 2.6 M | 1.1 M | 3.4 M | 7.1 M | 13.5 M | 18.5 M | 24.4 M | 24.4 M | 16.1 M | 16.3 M | 39.2 M | 41.2 M |
| ACHL | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 3.9 M | 16.6 M | 19.1 M | 18 M | 17 M | 13.9 M |
| NUVB | 902 K | 902 K | 902 K | 902 K | 902 K | 902 K | 902 K | 902 K | 902 K | 3.2 M | 6.6 M | 16.9 M | 13.2 M | 14 M | 10 M |
CytomX Therapeutics and related stocks such as Spero Therapeutics, Neoleukin Therapeutics, and Instil Bio Total Current Liabilities description
Total Current Liabilities is an item on CytomX Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of CytomX Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.My Equities
My Current Equities and Potential Positions
| CytomX Therapeutics | CTMX |
| Classification | Cancer Fighters |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.06
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.